ArticleBritish journal of cancer2004
SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- SLIT3-mediated intratumoral crosstalk induces neuroblastoma differentiation via a spontaneous regression-like program.Journal of translational medicine · 2025Article
- Article
- The potential of Slit2 as a therapeutic target for central nervous system disorders.Expert opinion on therapeutic targets · 2020Review
- Overlapping migratory mechanisms between neural progenitor cells and brain tumor stem cells.Cellular and molecular life sciences : CMLS · 2019Review
- Article
- Reduced USP33 expression in gastric cancer decreases inhibitory effects of Slit2-Robo1 signalling on cell migration and EMT.Cell proliferation · 2019Article
- Making Connections: Guidance Cues and Receptors at Nonneural Cell-Cell Junctions.Cold Spring Harbor perspectives in biology · 2018Review
- Epigenetics in renal cell cancer: mechanisms and clinical applications.Nature reviews. Urology · 2018Review
- Article
- Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Article
- The epigenetic landscape of renal cancer.Nature reviews. Nephrology · 2017Review
- Maximal Expression of the Evolutionarily Conserved Slit2 Gene Promoter Requires Sp1.Cellular and molecular neurobiology · 2016Article
- USP33 mediates Slit-Robo signaling in inhibiting colorectal cancer cell migration.International journal of cancer · 2015Article
- Reduced expression of Slit2 in renal cell carcinoma.Medical oncology (Northwood, London, England) · 2014Article
- SLIT2 inhibits cell migration in colorectal cancer through the AKT-GSK3β signaling pathway.International journal of colorectal disease · 2013Article
- The epigenetics of renal cell tumors: from biology to biomarkers.Frontiers in genetics · 2012Article
- Inactivation of SLIT2-ROBO1/2 pathway in premalignant lesions of uterine cervix: clinical and prognostic significances.PloS one · 2012Article
- Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.Virchows Archiv : an international journal of pathology · 2011Article
- Immunohistochemical staining of slit2 in primary and metastatic prostatic adenocarcinoma.Translational oncology · 2011Article
- Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis.Cell research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 3p21.3 RASSF1A tumour suppressor gene (TSG) provides a paradigm for TSGs inactivated by promoter methylation rather than somatic mutations. Recently, we identified frequent promoter methylation without somatic mutations of SLIT2 in lung and breast cancers, suggesting similarities between SLIT2 and RASSF1A TSGs. Epigenetic inactivation of RASSF1A was first described in lung and breast cancers and subsequently in a wide range of human cancers including neuroblastoma, Wilms' tumour and renal cell carcinoma (RCC). These findings prompted us to investigate SLIT2 methylation in these three human cancers. We analysed 49 neuroblastomas (NBs), 37 Wilms' tumours and 48 RCC, and detected SLIT2 promoter methylation in 29% of NB, 38% of Wilms' tumours and 25% of RCC. Previously, we had demonstrated frequent RASSF1A methylation in the same tumour series and frequent CASP8 methylation in the NB and Wilms' tumour samples. However, there was no significant association between SLIT2 promoter methylation and RASSF1A or CASP8 methylation in NB and RCC. In Wilms' tumour, there was a trend for a negative association between RASSF1A and SLIT2 methylation, although this did not reach statistical significance. No associations were detected between SLIT2 promoter methylation and specific clinicopathological features in the tumours analysed. These findings implicate SLIT2 promoter methylation in the pathogenesis of both paediatric and adult cancers and suggest that further investigations of SLIT2 in other tumour types should be pursued. However, epigenetic inactivation of SLIT2 is less frequent than RASSF1A in the tumour types analysed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.